Evidence map›Paper›PMID 41458179›Full record

ArticleMaterials today. Bio2025

PH20-modified exosomes loaded curcumin inhibit desmoplastic breast cancer by breaking extracellular matrix barrier and normalizing cancer-associated fibroblasts.

Xiaoxia Xue, Xiaoyu Li, Meng Tian, Liuchunyang Yu, JinXiu Qian, Xiuyun Bai, Jue Yang, Rongjun Deng, Qiqiong Liu, Ying Xing and 4 more

Abstract read
In one paragraph

Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Comparison of [European journal of nuclear medicine and molecular imaging · 2026
    Article
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Xiaoxia XueSchool of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, 100029, China.
Xiaoyu LiSchool of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, 100029, China.
Meng TianSchool of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, 100029, China.
Liuchunyang YuSchool of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, 100029, China.
JinXiu QianSchool of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, 100029, China.
Xiuyun BaiSchool of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, 100029, China.
Jue YangSchool of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, 100029, China.
Rongjun DengSchool of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, 100029, China.
Qiqiong LiuSchool of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, 100029, China.
Ying XingSchool of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, 100029, China.
Yuxing YaoSchool of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, 100029, China.
Cheng LuInstitute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, 100700, China.
Aiping LyuSchool of Chinese Medicine, Hong Kong Baptist University, Kowloon, 999077, Hong Kong, China.
Yuanyan LiuSchool of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, 100029, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC), a typical desmoplastic tumor, is characterized by dense fibrotic stroma enriched with cancer-associated fibroblasts (CAFs) and excessive extracellular matrix (ECM) deposition. Activated CAFs secrete abundant cytokine to promote tumor progression, while continuously recruit ECM proteins to form stiff pathological barriers that impede drug penetration and immune cell infiltration. In this work, we designed engineered exosomes co-modified with hyaluronidase PH20 (Exos-PH20) and curcumin (Cur) to specifically deliver Cur, aiming to breakthrough desmoplastic tumor microenvironment (TME) for deep tumor penetration, CAFs normalization rather than elimination, and amplification of anticancer efficacy. Results showed that Exos-PH20@Cur leverage the tumor-targeting capability of exosomes and PH20-mediated hyaluronan degradation to achieve deep intratumoral penetration. Meanwhile, the normalization of CAFs by suppressing PRMT5-strengthened Smad3-mediated fibrotic gene transcription, can alleviate TNBC fibrosis and even can disrupt TGF-β and IL-6 mediated crosstalk of CAFs with cancer cells to combat tumor invasion. As a result, the enhanced accumulation of Exos-PH20@Cur in tumor core, along with increased CD8

Indexed as

CAFsCurcuminDesmoplastic tumor microenvironmentEngineered exosomesTNBC

Identifiers

PMID41458179
PMCPMC12743558

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.